Observational studyCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2- Metastatic Breast Cancer.
Observational study in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of socioeconomic status on tumor stage, molecular subtype distribution, treatment adherence, and survival outcomes in breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer treated in the United States based on these factors.
methodsA retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2- metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan-Meier methods.
resultsThe analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1-Q3) versus higher (Q4-Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.
conclusionsWe observed disparities in first-line treatment and outcomes among women with HR+/HER2- metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. IMPACT: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.